Citius Pharmaceuticals Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while iShares Broad USD Investment Grade Corporate Bond trades at $50.21. The key difference: Citius Pharmaceuticals Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| CTXR | USIG | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $52.69 |
52-Week Low | $0.48 | $50.18 |
Enterprise Value | $16.23M | — |
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →